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Editorial summary: 
Bioluminescence+resonance+energy+transfer,+from+the+substrate+of+a+luciferase+fused+to+a+G+
protein8coupled+receptor+to+a+fluorescent+dye+covalently+linked+to+a+receptor+ligand,+allows+the+
profiling+of+ligand+affinity+and+binding+kinetics.++
 
Bioluminescence resonance energy transfer (BRET) is a well-established method for 
investigating protein-protein interactions. Here we present a BRET approach to 
monitor ligand binding to G protein-coupled receptors (GPCRs) on the surface of 
living cells made possible by the use of fluorescent ligands in combination with a 
bioluminescent protein (NanoLuc) that can be readily expressed on the N-terminus of 
GPCRs. 
The ability to monitor protein-protein or drug-protein interactions with ease and sensitivity 
is the cornerstone of cell biology and pharmacology. Bioluminescence resonance energy 
transfer (BRET) is dependent upon energy transfer between a bioluminescent donor 
(luciferase oxidizing its substrate) and fluorescent acceptor. It has become the proximity 
assay of choice for many researchers due to its ease of use and capacity for real time 
monitoring in live cells1,2,3. Renilla luciferase variant Rluc8 and green fluorescent protein 
variant Venus are a notable example of a BRET combination4, however various donor-
acceptor pairs have been utilized successfully for different applications1. To date, drug-
protein interactions have not been directly studied using BRET, although it has recently 
been shown that BRET can be used to detect drug concentration using bioluminescent 
sensor proteins5. However, the successful development of many different fluorescent 
agonists and antagonists for G protein-coupled receptors (GPCRs)6 provides an opportunity 
for them to be used as energy acceptors to measure BRET between fluorescently-labeled 
ligand and luciferase-tagged receptor. 
We have developed an assay that can measure ligand binding to GPCRs using BRET in 
living cells. We initially investigated whether β2-adrenoceptors (β2ARs) tagged on their 
extracellular N-terminus with a luminescent protein can be expressed in living cells. We 
assessed Rluc8 and recently described NanoLuc (Nluc)7 luciferase engineered from the 
luciferase found in deep sea shrimp, Oplophorus. In HEK293 cells, increasing levels of 
transiently-transfected cDNA in the presence of luciferase substrates coelenterazine h for 
Rluc8 and furimazine for Nluc caused concurrent increases in luminescence with both 
Rluc8- and Nluc-tagged β2AR. Nluc-β2AR produced substantially greater luminescence 
signals than Rluc8-β2AR, and with a spectrum left-shifted by circa 20 nm (Supplementary 
Fig. 1). We initially selected a TAMRA-labeled (carboxytetramethylrhodamine) β2AR 
antagonist (alprenolol-TAMRA) as a fluorescent acceptor ligand since it has spectral 
characteristics theoretically amenable both for accepting energy from either bioluminescent 
protein donors (peak excitation at 565 nm), and for emitting light at wavelengths that can 
be clearly distinguished from luciferase light emission (peak emission at 580 nm). We 
added increasing concentrations of TAMRA-labeled alprenolol to HEK293 cells 
transiently-transfected with luciferase tagged-β2AR prior to direct addition of luciferase 
substrate in continued presence of fluorescent ligand. We could readily detect receptor 
specific binding using Nluc as the BRET donor but not when Rluc8 was used (Fig. 1a,b). 
The main reason for this is likely to be the capacity of these N-terminally Nluc-tagged 
receptors to traffic appropriately to the plasma membrane (Supplementary Fig. 2). Thus, 
we observed a clear concentration-dependent ligand-binding BRET signal in cells 
expressing Nluc-β2AR, which was completely prevented by competition with a high 
concentration (10 µM) of unlabeled alprenolol (Fig. 1b). 
To test compatibility with various fluorophores, we used fluorescent propranolol 
derivatives conjugated to either BODIPY-630/650 (excitation 630 nm, emission 650 nm; 
propranolol-BY630) or BODIPY-FL (excitation 503 nm, emission 512 nm; propranolol-
BYFL) combined with Nluc-β2AR (Fig. 1c,d). We observed specific binding with both 
fluorescent ligands, which was inhibited by agonist isoprenaline, and antagonists 
propranolol, ICI 118551 and CGP 12177. Therefore Nluc has a substantial dynamic range 
compatible with excitation wavelengths of both BODIPY-630/650 and BODIPY-FL 
fluorophores. We observed a reduced signal-to-background ratio with propranolol-BYFL 
(Supplementary Fig. 3), which is due to the large degree of donor background present in 
the BRET acceptor channel. Consequently BODIPY-630/650 is generally a preferred 
choice of acceptor. However, despite suboptimal performance with the BODIPY-FL, our 
results support use of a variety of fluorescent dyes as potentially robust tracers for ligand 
binding applications for GPCRs. We calculated KD values indicating the affinity of 
propranolol-BY630 and propranolol-BYFL (mean ± s.e.m.) from saturation binding assays 
as 18.9 ± 4.1 nM (n=6) and 42.8 ± 10.8 nM (n=8) respectively. Subsequently, we calculated 
the respective pKi values indicating the affinity of propranolol, ICI 118551 and CGP12177 
from the corresponding IC50 values using the Cheng-Prusoff Equation: 8.13 ± 0.05, 8.04 ± 
0.04, 8.32 ± 0.03 (competing with propranolol-BY630) and 8.89 ± 0.09, 8.69 ± 0.14, 8.92 ± 
0.03 (competing with propranolol-BYFL). These values (particularly those obtained with 
propranolol-BYFL) are comparable to those obtained by Baker (2005)8. As with distinct 
radioligands acting on the same receptor, different fluorophores may result in a ligand 
exhibiting slightly different affinities9 and binding modes. This could potentially shift 
apparent affinities of competing ligands due to the probe-dependency of cooperative 
interactions between protomers within a receptor complex10. This factor may also influence 
fluorophore choice, opening up interesting avenues of potential research into cooperativity 
mechanisms by utilising multiple fluorescent ligands (see below).  
To further exemplify BRET ligand binding with multiple fluorescent ligands, we used 
HEK293 cells stably-transfected with N-terminally Nluc-labeled adenosine A1 or A3 
receptors and treated them with increasing concentrations of the BODIPY-630/650-labeled 
antagonist CA20064511. We determined non-specific binding using a high concentration of 
unlabelled antagonist (DPCPX for Nluc-A1 or MRS 1220 for Nluc-A3) and measured 
BRET after direct furimazine addition. We observed a saturable signal for both receptors 
with low non-specific binding (Fig. 2a,b) across the full concentration range of fluorescent 
ligand. KD values for specific binding were 7.5 ± 2.4 nM for Nluc-A1 and 7.6 ± 3.7 nM for 
Nluc-A3 (mean ± s.e.m. of n=4), consistent with unmodified receptors12. In addition, we 
examined kinetics of CA200645 binding to Nluc-A1 (Supplementary Fig. 4), yielding a 
similar KD to that obtained with saturation binding (20.4 ± 6.9 nM, n=3, p>0.05 unpaired t-
test vs saturation KD). As affinity values for CA200645 at both adenosine receptors were 
very similar, it was important to confirm that the specific ligand binding BRET signals 
generated had the appropriate pharmacology for the specific receptor under study, and were 
not simply a consequence of non-specific membrane interactions due to the lipophilicity of 
BODIPY. We used an A3-selective fluorescent ligand AV039 (compound 19 in ref. 13) 
containing the same BODIPY fluorophore and tested its ability to bind to Nluc-A1 (Fig. 2c) 
and Nluc-A3 (Fig. 2d) expressing cells. We did not detect a saturable specific BRET signal 
at Nluc-A1 at concentrations of AV039 up to 500 nM (Fig. 2c). In contrast, we detected 
clear specific binding at Nluc-A3 (Fig. 2d) yielding a KD for AV039 of 24.6 ± 8.3 nM. 
We then investigated the ability of a panel of ligands to inhibit specific binding of 
CA200645 to Nluc-A1 and Nluc-A3 (Fig. 2e,f and Supplementary Fig. 5) and calculated 
affinity (pKi) values (Supplementary Table 1). Importantly the A1-selective antagonist 
DPCPX showed high affinity at Nluc-A1 and low affinity at Nluc-A3 and conversely the A3-
selective antagonist MRS1220 showed high affinity at Nluc-A3 and lower affinity at Nluc-
A1.  Furthermore, affinities were comparable to those obtained using radioligand binding 
assays14 (Supplementary Table 1). We also obtained comparable results with the A3-
selective ligand AV039 in Nluc-A3 cells (Supplementary Fig. 6 and Supplementary 
Table 2).  
To determine whether the BRET ligand-binding assay was applicable to fluorescent 
agonists, we also undertook experiments with a fluorescent adenosine receptor agonist, 
ABEA-X-BY63015. In saturation binding experiments, we observed a clear saturable BRET 
signal at both Nluc-A3 (Fig. 2g) and Nluc-A1 (Supplementary Fig. 7a). ABEA-X-BY630 
had a higher affinity for Nluc-A3 (KD = 38.4 ± 13.7 nM) than Nluc-A1 (KD = 167.0 ± 74.4 
nM). Competition binding assays with ABEA-X-BY630 and the panel of eight ligands used 
above yielded comparable affinities to those obtained with the antagonist fluorescent 
ligands (Fig. 2h, Supplementary Fig. 7 and Supplementary Table 2). Again, affinities 
were comparable to those obtained using radioligand binding assays14 (Supplementary 
Table 2). However, we obtained subtle differences in pKi values for non-fluorescent 
competing ligands with different fluorescent ligands, particularly in the case of Nluc-A3 
(Supplementary Fig. 8). This would be in keeping with known allosterism across the A3 
homodimer interface10. Interestingly, we observed a similar phenomenon with the β2-
adrenoceptor (Fig. 1) that is also known to form homodimers16.  
We used a similar fluorescent agonist strategy to investigate ligand binding to a peptide 
receptor (angiotensin II receptor type 1; AT1) using a TAMRA-labelled angiotensin II 
(TAMRA-AngII). We performed competition BRET binding assays to investigate the 
ability of three AT1 ligands (angiotensin II, candesartan and olmesartan) to reduce the 
BRET signal. We observed a clear, concentration-dependent decrease in BRET signal in 
the presence of competing compounds (Fig. 2i), with olmesartan exhibiting highest affinity. 
To demonstrate assay sensitivity, we carried out competition binding assays at Nluc-AT1 
using varying concentrations of TAMRA-AngII and found at concentrations down to 100 
nM TAMRA-AngII a specific signal was still observed that could be reduced by all three 
competing compounds (Supplementary Fig. 9).  
Traditionally, binding assays have used radioactive ligands to probe targets; however, this 
has become increasingly costly and undesirable for practical reasons17,18. Furthermore, for 
technical reasons, many of the ligand-receptor affinities published in the literature have 
been derived using cell membranes assayed at 4°C, with assumptions made about 
applicability to receptors in live cells at 37°C. More recently, FRET ligand binding assays 
have been developed and successfully utilized17,19, setting a precedent for applicability of 
resonance energy transfer approaches. However, there are a number of reasons why BRET 
is distinct from FRET, and indeed, is often used in preference1. This study has 
demonstrated that BRET ligand binding assays provide an exciting alternative to 
radioligand binding assays, with the important advantage of being able to monitor ligand-
receptor interactions in live cells, at 37°C and in real-time. Separation of free and bound 
fluorescent ligand is not required due to the exquisite distance-dependence of BRET20, nor 
is an additional step of conjugating a fluorophore to the N-terminal domain of the receptor 
of interest, as required with SNAP/CLIP technology commonly used with time-resolved 
FRET17. Indeed, as illustrated by our data, no wash steps or lysis are required, making this 
approach truly homogenous. Consequently BRET ligand binding has considerable potential 
for future drug discovery and profiling applications. 
 
METHODS 
Methods and any associated references are available in the online version of the paper. 
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FIGURE LEGENDS 
 
Figure 1 " Suitability of NanoLuc for BRET binding studies. (a,b) BRET ligand binding 
assays for transiently-transfected Rluc8-β2AR (a) and Nluc-β2AR (b) treated with 
increasing concentrations of alprenolol-TAMRA in the absence or presence of 10 µM 
unlabeled alprenolol. Data are mean ± s.e.m. of three experiments performed in 
quadruplicate. (c,d) Inhibition of the BRET signal for HEK293 cells stably-expressing 
Nluc-β2AR treated with 10 nM propranolol-BY630 (c) or propranolol-BYFL (d) and 
increasing concentrations of unlabelled ligands as shown. Each data point represents mean 
± s.e.m. of five (all curves in (c) and propranolol in (d)) or four (d) separate experiments.  
In each experiment we made triplicate determinations for each data point.  
 
Figure 2 " Extending use of NanoBRET. (a,b) We treated Nluc-A1 (a) and Nluc-A3 (b) 
with increasing CA200645 concentrations with non-specific binding established with 1 µM 
DPCPX for Nluc-A1 (a) and 1 µM MRS 1220 for Nluc-A3 (b). (c,d) We treated Nluc-A1 
(c) and Nluc-A3 (d) with increasing AV039 concentrations in the absence and presence of 1 
µM DPCPX (c) or 1 µM MRS 1220 (d). In (c), the only statistically significant difference 
was at 250 nM AV039 (two-way ANOVA; p<0.05). (e,f) We treated Nluc-A1 (e) and Nluc-
A3 (f) cells with 25 nM CA200645 and increasing unlabeled ligand concentrations. (g) We 
generated saturation BRET binding curves for binding fluorescent agonist ABEA-X-
BY630 to Nluc-A3 in absence or presence of 1µM MRS 1220. (h) We monitored the ability 
of increasing concentrations of DPCPX, SCH 58261, MRS 1220 and CGS 15943 to 
decrease Nluc-A3 to ABEA-X-BY630 BRET. (i) We treated Nluc-AT1 with 1 µM 
TAMRA-AngII and increasing concentrations of angiotensin II, candesartan and 
olmesartan. We measured BRET after furimazine addition. Panels a, b, c, d and g are 
representative of four experiments (in triplicate; error bars are s.e.m. of triplicate points). 
Data in e, f, h and i represent mean ± s.e.m. of three experiments (in duplicate; i) or four 
experiments (in triplicate; e, f, h). Exceptions are DPCPX in (e) which is mean ± s.e.m. of 
five experiments (in triplicate) and MRS1220 in (f) which is mean ± s.e.m. of three 
experiments (in triplicate).  


ONLINE METHODS 
cDNA constructs. We cloned β2AR and AT1 receptor cDNAs into a pF-sNnK vector 
(Promega), encoding a fusion of the secretory signal peptide sequence of IL6 on the N-
terminus of NanoLuc (Nluc). The resulting open reading frame (ORF) therefore encoded a 
fusion of secreted Nluc at the N-terminus of β2AR or AT1 receptor, with Gly-Ser-Ser-Gly 
linkers between the Nluc ORF and the GPCR ORF. N-terminally Rluc8-labeled β2AR was 
generated by substituting the Nluc ORF for the Rluc8 ORF. We generated Nluc-labeled 
adenosine receptor constructs by amplifying the full length sequence of Nluc luciferase (as 
provided by Promega in the pNL1.1 vector) and fusing it in frame with the membrane 
signal sequence of the 5HT3A receptor within pcDNA3.1 to yield sig-Nluc. We then fused 
the full-length human sequence of the adenosine receptor of choice (with the methionine 
start signal removed) to the 3’ end of the sig-Nluc in pcDNA3.1. This gave the constructs 
designated as Nluc-A1 receptor and Nluc-A3 receptor, both of which include the signal 
sequence. 
Ligands. CA200645, propranolol-BY630 (propranolol-βalanine-βalanine-X-BODIPY-
630/650) and propranolol-BYFL (propranolol-βalanine-βalanine-X-BODIPY-FL) were 
from CellAura. AV039 and ABEA-X-BY630 (ABEA-X-BODIPY-630/650) were 
synthesised by the University of Nottingham as described by Vernall et al.13 and Middleton 
et al.15.  Alprenolol-TAMRA was synthesised by Promega. TAMRA-AngII was from 
AnaSpec. Alprenolol and angiotensin II were from Sigma. Candesartan and olmesartan 
were from Zhou Fang Pharm Chemical. DPCPX, SCH 58261, MRS 1220, CGS 15943, ZM 
241385, XAC, PSB 603, isoprenaline, propranolol, ICI 118551 and CGP 12177 were from 
Tocris. 
Stable cell line generation. We maintained HEK293 cells (for Nluc-A1; from ATCC) or 
HEK293G cells (GlosensorTM cAMP HEK293 for Nluc-A3; from Promega) in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 10% fetal calf serum (FCS) and 2 mM L-
glutamine at 37°C, 5% CO2. We generated mixed population cell lines by transfecting the 
required Nluc-adenosine receptor construct using Lipofectoamine (Life Technologies) 
according to the manufacturer’s instructions and then subjecting the cells to selective 
pressure (1 mg/ml G418) for 2–3 weeks. We then dilution cloned the Nluc-A1 and A3 
receptor cell lines to obtain cell lines originating from a single cell. The Nluc-β2AR stable 
cell line was from Promega. We confirm that all cell lines used were mycoplasma free. 
BRET β2AR ligand binding assays. We carried out transient transfections of HEK293 
cells (ATCC) using FuGENE (Promega) at a 3:1 lipid:DNA ratio. We then seeded cells and 
lipid-DNA complexes into 96-well plates at a density of 20,000 cells per well (in DMEM 
supplemented with 10% FCS (Gibco)), with 50 ng of DNA per well. 24 hours post-
transfection, we removed the media from each well and replaced it with OptiMEM without 
phenol red (Gibco). For experiments using alprenolol-TAMRA, we then incubated for 180 
min in OptiMEM (without phenol red). We then added serially-diluted alprenolol-TAMRA 
in the absence or presence of 10 µM alprenolol and incubated for 120 min at room 
temperature. We then added the required substrate (furimazine for Nluc-β2AR and 
coelenterazine h for Rluc8-β2AR) to a final concentration of 10 µM. We then measured 
BRET using the CLARIOstar plate reader (BMG Labtech) at room temperature. We 
sequentially measured filtered light emissions at 450 nm (80 nm bandpass) and >610 nm 
(longpass), and calculated the raw BRET ratio by dividing the >610 nm emission by the 
450 nm emission. For competition experiments using fluorescent-propranolol derivatives, 
we incubated Nluc-β2AR stably-transfected HEK293 cells with 10 nM propranolol-BY630 
or propranolol-BYFL and the required concentration of competing ligand diluted in HEPES 
buffered saline solution (HBSS, 25 mM HEPES, 10 mM glucose, 146 mM NaCl, 5 mM 
KCl, 1 mM MgSO4, 2 mM sodium pyruvate, 1.3 mM CaCl2) for 1 h at 37°C. For saturation 
experiments, we incubated β2AR cells with increasing concentrations of propranolol-
BY630 or propranolol-BYFL in the presence or absence of 1 µM propranolol for 1 h at 
37°C. We then measured the luminescence and fluorescence using the PHERAstar FS plate 
reader (BMG Labtech) at room temperature.  We measured filtered light emissions at 460 
nm (80 nm bandpass) and 535 nm (60 nm bandpass) for propranolol-BYFL and at 460 nm 
(80 nm bandpass) and >610 nm (longpass) for propranolol-BY630. We calculated the raw 
BRET ratio by dividing the >610 nm emission or 535 nm emission by the 460 nm emission. 
We have adopted the term ‘raw BRET ratio’ as no background ratio has been subtracted. 
BRET A1 and A3 receptor ligand binding assays. We performed saturation and 
competition binding assays on stably-transfected cells that we seeded 24 h prior to 
experimentation in white Thermo Scientific Matrix 96-well microplates. We removed the 
media from each well and replaced it with HBSS with the required concentration of 
fluorescent ligand and competing ligand. For pre-incubation experiments with ABEA-X-
BY630, we incubated competing unlabeled ligand for 30 min prior to the addition of 250 
nM ABEA-X-BY630 for Nluc-A1 expressing cells and 50 nM ABEA-X-BY630 for Nluc-
A3 expressing cells. For saturation and competition experiments, upon the addition of 
fluorescent ligand we incubated cells for 1 h at 37°C (no CO2) and then added the Nluc 
substrate furimazine (Promega) to a final concentration of 10 µM. For association kinetic 
experiments on Nluc-A1 expressing cells, we removed media from each well, replaced it 
with HBSS containing 10 µM furimazine and incubated for 15 min at room temperature in 
the PHERAstar FS plate reader (BMG Labtech) to allow the signal to reach equilibrium.  
We then added the required concentration of CA200645, immediately reinserted the plate 
and read every well once per min for 60 min. For all experiments, we measured the 
luminescence and resulting BRET using the PHERAstar FS plate reader (BMG Labtech) at 
room temperature. We again sequentially measured filtered light emissions at 460 nm (80 
nm bandpass) and >610 nm (longpass), and calculated the raw BRET ratio by dividing the 
>610 nm emission by the 460 nm emission.  
BRET AT1 receptor ligand binding assays. We maintained HEK293FT cells (Life 
Technologies) at 37°C, 5% CO2 in complete medium (Dulbecco’s modified Eagle’s 
medium (DMEM) containing 0.3 mg/ml glutamine, 100 IU/ml penicillin, and 100 µg/ml 
streptomycin) supplemented with 10% FCS (Gibco). We carried out transient transfections 
in a 96-well plate using FuGENE (Promega). For each well we incubated 1 ng of Nluc-AT1 
receptor cDNA and 49 ng of pcDNA3 (Life Technologies) for 10 min at room temperature 
with a mix of 0.5 µl of FuGENE and 49.5 µl of serum-free DMEM (pre-incubated at room 
temperature for 5 min). We then incubated cells (105 in 150 µl/well) in DMEM 
supplemented with 10% FCS with the final DNA-FuGENE mix (50 µl/well). We carried 
out assays 48 h post transfection after removing medium. We treated cells with competitor 
ligand for 30 min followed by addition of TAMRA-AngII for a further 30 min. We carried 
out ligand incubations at 37°C, 5% CO2. We then added the Nluc substrate furimazine 
(Promega) to a final concentration of 10 µM and measured luminescence immediately. We 
measured BRET at 37°C using the PHERAStar FS plate reader (BMG Labtech). We 
sequentially measured filtered light emissions at 460 nm (80 nm bandpass) and >610 nm 
(longpass), and calculated the raw BRET ratio by dividing the >610 nm emission by the 
460 nm emission. 
Measurement of Nluc and Rluc8 emission spectra. To determine the emission spectra of 
Nluc and Rluc8, we transiently transfected HEK293 cells (ATCC) with the expression 
constructs for Nluc-β2AR and Rluc8-β2AR as described above for the β2AR ligand binding 
assays. 24 hours post-transfection, we removed the media from each well and replaced it 
with OptiMEM without phenol red (Gibco), followed by incubation for 180 min at 37°C.  
Immediately prior to measurement we added the luciferase substrates furimazine (Nluc) or 
coelenterazine h (Rluc8) at a final concentration of 10 µM. We then determined the 
emission spectra with a CLARIOstar plate reader (BMG Labtech) using the luminescent 
scanning option (20 nm bandwidth, 1 nm resolution, integration time 500 msec, gain 3000). 
Bioluminescent imaging of Nluc-β2AR and Rluc8-β2AR. We performed bioluminescent 
imaging experiments to determine the localization of the Nluc-β2AR and Rluc8-β2AR 
fusion proteins. We performed all imaging experiments using the Olympus LV200 
bioluminescence microscope equipped with a Hamamatsu ImagEM EMCCD camera and a 
100x/1.4 UPLanSApo. We transfected HEK293 cells with expression constructs for Nluc-
β2AR and Rluc8-β2AR, plated in 35 mm optically clear dishes (Ibidi) at a density of 
200,000 cells per dish in 2 ml growth medium (DMEM supplemented with 10% FCS) and 
incubated for 24 h in a tissue culture incubator.  We then replaced the growth medium with 
1 ml OptiMEM followed by incubation for 180 min at 37°C. Immediately prior to image 
acquisition, we replaced the media with OptiMem including the luciferase substrates 
furimazine (Nluc) or coelenterazine h (Rluc8) at a final concentration of 10 µM. We 
identified suitable fields of view based on imaging of total luminescent signal of the donor 
fusion. We acquired images using an EM gain of 200 and exposure times of 1 sec (Nluc-
β2AR) and 20 sec (Rluc8-β2AR). We acquired all images using Olympus cellSens software 
and performed image processing with ImageJ software. 
Data presentation and statistical analysis. We presented and analysed data using Prism 
software (GraphPad).  
We simultaneously fitted the total and non-specific saturation binding curves using the 
following equation:  !"#$!!"#$% = !!!"#×[!]! + !! + ! !!×[!] + !  
 
where Bmax is the maximal response, [B] is the concentration of fluorescent ligand in nM, 
KD is the equilibrium dissociation constant in nM, M is the slope of the non-specific 
binding component and C is the intercept with the Y-axis.  
 
We fitted the competition binding curves to calculate the Ki of the unlabeled ligands using 
the Cheng-Prusoff equation: !! = !"!"1+ [!]!! 
 
where [L] is the concentration of fluorescent ligand in nM and KD is the KD of fluorescent 
ligand in nM. The calculated KD values used were as calculated from the saturation binding 
experiments.  The IC50 is calculated from the following equation: 
 %!!"ℎ!"!#!$%!!"!!"#$%&%$!!"#$"#% = ! 100!×[!]! + !!"!" 
where [A] is the concentration of competing drug and the IC50 is the molar concentration of 
ligand required to inhibit 50% of the specific binding of concentration [L] of the fluorescent 
ligand.  We also used this equation to fit concentration-inhibition data where the affinity of 
the labelled ligand is unknown. 
 
From association kinetic data, we obtained kon, koff and KD values from the following 
equation: !! = !!!""!!"  
+
Where KD is the equilibrium dissociation constant, koff is the dissociation rate constant of 
the ligand in min–1 and kon is the association rate constant in M–1 min–1 and is calculated as 
follows: 
 !!" = !!!"# − !!!""[!]  
 
Where [L] is the ligand concentration in M and kobs is calculated from global fitting of the 
data to the following monoexponential association function: 
 ! = !!"#!. (1− !!!!"#!.!!!) 
 
Where Ymax equals levels of binding at infinite time (t) and kobs is the rate constant for the 
observed rate of association.   
 
We carried out statistical analysis using unpaired t-test or ANOVA as appropriate (P<0.05). 
The n values in the text refer to the number of separate repeat experiments.  Based on our 
experience, a minimum of three repeat experiments, a power of 98% and a P value of 0.05, 
will give a standardized difference of interest (e.g. a difference in pKi values) of 
approximately 0.5 using the NanoBRET ligand binding assay.   
 
 
 
 Supplementary Figure 1 
Comparison of Rluc8-β2AR and Nluc-β2AR luminescence spectra 
We generated luminescence spectra with HEK293 cells transiently transfected with Rluc8-β2AR or Nluc-β2AR following addition of 
coelenterazine h or furimazine substrate respectively. (a) Presentation as normalized luminescence illustrates that the Nluc emission 
peak is left-shifted by about 20 nm compared to Rluc8, thus enabling better spectral separation from the acceptor emission. (b) 
Presentation of the same spectra in terms of measured luminescence in relative light units (RLU) without normalization to the peak 
emission. This illustrates the substantially greater luminescence, and therefore energy transfer potential, of Nluc compared to Rluc8 
despite the spectrum being left-shifted (Nluc peak (462 nm): 113,909 RLU; Rluc8 peak (480 nm): 1642 RLU). This becomes more 
relevant as more red-shifted energy acceptors are utilized, and therefore the spectral overlap of the donor emission spectrum with the 
acceptor excitation spectrum diminishes. The high luminescence output of Nluc means that this reduced overlap is much less of an 
issue compared with Rluc8. The data shown here are representative of three independent experiments. 
 
Supplementary Figure 2 
Microscopy images comparing the cellular localization of Rluc8-β2AR and Nluc-β2AR 
(a) Images of HEK293 cells transiently transfected with Rluc8-β2AR indicate that this fusion protein is not appropriately trafficked to the 
plasma membrane. (b) This is in contrast to Nluc-β2AR that is clearly localized at the plasma membrane. We acquired images of eight 
different fields of view per sample and two representative fields are shown. Furthermore, the data are representative of three 
independent experiments. Nluc is derived from the luciferase expressed in deep sea shrimp Oplophorus gracilirostris. The native 
luciferase is secreted by the shrimp in bright luminescent bursts to ward off predators1. It has therefore evolved to be secreted and 
therefore pass through cellular membranes. This is not the case for Renilla luciferase. Indeed multiple attempts have been made to 
generate a secreted Renilla luciferase2. However, addition of the signal peptide of human interleukin-2 resulted in a secreted form of 
Rluc with 15 times less activity than cytosolic Rluc in mammalian cells3. The reason for this was unclear, but one suggested possibility 
was that addition of the signal peptide resulted in misfolding in the endoplasmic reticulum. 
1. Hall, M.P. et al. ACS Chem. Biol. 7, 1848–1857 (2012). 
2. Tannous, B.A. & Teng, J. Biotechnol. Adv. 29, 997–1003 (2011). 
3. Liu, J, O'Kane D.J., Escher, A. Gene 203, 141–148 (1997). 
 Supplementary Figure 3 
BRET binding assessed with propranolol-BY630 and propranolol-BYFL 
(a,b) We treated HEK293 cells stably expressing Nluc-β2AR with 10 nM propranolol-BY630 (a) or 10 nM propranolol-BYFL (b) and 
increasing concentrations of unlabeled ligands as shown. In the presence of 10 µM propranolol we observed a decrease of 69.2 ± 1.3% 
in propranolol-BY630 BRET signal, whereas with propranolol-BYFL we only achieved a 25.6 ± 1.2% decrease in signal. Each data point 
represents mean ± s.e.m. of five (all curves in (a) and propranolol in (b)) or four (b) separate experiments. In each experiment we made 
triplicate determinations for each data point. 
 
 
Supplementary Figure 4 
Kinetic measurements of binding of CA200645 to Nluc-A1 receptor 
We treated HEK293 cells stably expressing Nluc-A1 receptor with various concentrations of CA200645. We measured BRET between 
Nluc and the fluorescent ligand every min for 60 min at room temperature. The data shown are representative of three independent 
experiments performed in triplicate. From global fitting of the data, the kinetic parameters for CA200645 at Nluc-A1 receptor are kon = 
9.64 ± 0.32 x 105 M–1 min–1 and koff = 0.019 ± 0.005 min–1 with a resulting KD of 20.4 ± 6.9 nM (mean ± s.e.m., n=3). 
 
 Supplementary Figure 5 
Inhibition of BRET between NanoLuc and CA200645 at the adenosine A1 and A3 receptors by four additional compounds 
(a,b) We treated HEK293 cells stably expressing Nluc-A1 receptor (a) or Nluc-A3 receptor (b) with 25 nM CA200645 and increasing 
concentrations of unlabeled ligands as shown. We monitored the resulting concentration dependent decrease in BRET and each data 
point represents mean ± s.e.m. of five (a: propranolol, ZM241385), four (a: XAC, PSB 603; b: PSB 603) or three (b: propranolol, 
ZM241385, XAC) experiments performed in triplicate. 
 
 Supplementary Figure 6 
Inhibition of BRET between NanoLuc and AV039 at the adenosine A3 receptor by a panel of eight GPCR antagonists 
(a,b) We treated HEK293 cells stably expressing Nluc-A3 receptor with 10 nM AV039 and increasing concentrations of unlabeled 
ligands as shown. The resulting concentration dependent decrease in BRET was monitored and each data point represents mean ± 
s.e.m. of four experiments performed in triplicate.  
 
 
Supplementary Figure 7 
Saturation and competition ligand binding with ABEA-X-BY630 at Nluc-A1 and Nluc-A3 receptors 
(a) We treated HEK293 cells stably expressing Nluc-A1 receptor with increasing concentrations of ABEA-X-BY630. We established 
non-specific binding in the presence of 1 µM DPCPX and measured the resulting BRET ratios after 1 h incubation at 37 °C.  (b–d) We 
also performed competition BRET binding assays on Nluc-A1 (b, c) and Nluc-A3 (d) receptor-expressing HEK293 cells treated with 250 
nM ABEA-X-BY630 (b, c) or 50 nM ABEA-X-BY630 (d), along with increasing concentrations of unlabeled ligands as shown.  Panel a is 
a representative graph of three experiments performed in triplicate. Data points in b, c and d represent mean ± s.e.m. of four 
experiments performed in triplicate.  
 
 
Supplementary Figure 8 
A comparison of pKi values obtained at the adenosine A1 and A3 Nluc-tagged receptors using three different fluorescent 
ligands 
(a,b) We obtained pKi values for (a) the Nluc-A1 receptor and (b) the Nluc-A3 receptor with the non-selective fluorescent antagonist 
CA200645, non-selective fluorescent agonist ABEA-X-BY630 and A3-selective fluorescent antagonist AV039. We have taken pKi 
values from Supplementary Tables 1 and 2 (see tables for n numbers). * indicates values which are significantly different (p<0.05) using 
an unpaired t-test (a) or one-way ANOVA (b). In (b) the ANOVA analysis shows that for most competing ligands (with the exception of 
PSB 603) the data for each competing ligand cannot be described by a single pKi value. 
 
 
Supplementary Figure 9 
Competition ligand binding at Nluc-AT1 receptor with varying concentrations of TAMRA-AngII 
(a–c) We treated cells transiently expressing Nluc-AT1 receptor with 1, 0.6, 0.3, 0.1 or 0 µM TAMRA-AngII and increasing 
concentrations of (a) angiotensin II, (b) candesartan and (c) olmesartan. We measured BRET between Nluc and TAMRA-AngII. Data 
points represent mean ± s.e.m. of three experiments performed in duplicate.  
 !
Supplementary Table 1  
pKi and reference values for compounds binding to Nluc-labeled A1 and A3 receptors 
a We obtained pKi values (mean ± s.e.m.) in the NanoBRET binding assay using whole, 
live HEK293 cells expressing Nluc-A1 or Nluc-A3 receptor and 25 nM CA200645. 
b Previously published pKi values and associated references as listed in IUPHAR/BPS 
Guide to Pharmacology (www.guidetopharmacology.org). 
Note: Using 3H-DPCPX in live CHO cells expressing the wild-type A1 receptor, we have 
previously published pKi values for DPCPX, XAC and CGS15943 of 8.37 ± 0.03, 7.25 ± 
0.02 and 8.35 ± 0.05 respectively20. These are very similar to the respective values quoted 
for Nluc-A1 receptor with CA200645 above. 
1.  de Ligt, R.A., Rivkees, S.A., Lorenzen, A., Leurs, R. & Ijzerman, A.P. Eur. J. 
Pharmacol. 510, 1–8 (2005). 
2.  Iredale, P.A., Alexander, S.P. & Hill, S.J. Br. J. Pharmacol. 111, 1252–1256 (1994). 
3.  Obiefuna, P.C. et al. J. Pharmacol. Exp. Ther. 315, 329–336 (2005). 
4.  Rivkees, S.A., Barbhaiya, H. & AP, I.J. J. Biol. Chem. 274, 3617–3621 (1999). 
5.  Weyler, S. et al. ChemMedChem 1, 891–902 (2006). 
6.  Auchampach, J.A., Jin, X., Wan, T.C., Caughey, G.H. & Linden, J. Mol. Pharmacol. 
52, 846–860 (1997). 
7.  Hayallah, A.M. et al. J. Med. Chem. 45, 1500–1510 (2002). 
8.  Klotz, K.N. et al. Naunyn Schmiedebergs Arch. Pharmacol. 357, 1–9 (1998). 
9.  Salvatore, C.A., Jacobson, M.A., Taylor, H.E., Linden, J. & Johnson, R.G. Proc. Natl. 
Acad. Sci. U S A 90, 10365–10369 (1993). 
10. Varani, K. et al. Mol. Pharmacol. 57, 968–975 (2000). 
11. Jacobson, K.A. & Gao, Z.G. Nat. Rev. Drug. Discov. 5, 247–264 (2006). 
12. Ongini, E., Dionisotti, S., Gessi, S., Irenius, E. & Fredholm, B.B. Naunyn 
Schmiedebergs Arch. Pharmacol. 359, 7–10 (1999). 
13.  Townsend-Nicholson, A. & Schofield, P.R. J. Biol. Chem. 269, 2373–2376 (1994). 
14.  Jacobson, K.A. et al. Neuropharmacology 36, 1157–1165 (1997). 
 Nluc-A1 receptor Nluc-A3 receptor 
pKia n pKi in 
literatureb 
Refb pKia n pKi in 
literatureb 
Refb 
DPCPX 8.17 ± 0.10 5 7.4-9.2 1-5 6.93 ± 0.09 4 5.4-6.6 5-10 
SCH 58261 6.65 ± 0.16 4 6.1-6.3 11-13 6.80 ± 0.14 4 5.9 11 
MRS 1220 6.89 ± 0.20 4 - - 9.20 ± 0.08 3 8.2-9.2 14-17 
CGS 15943 8.04 ± 0.08 4 8.5 12 8.12 ± 0.10 4 7.0-7.9 8,10,12,15 
Propranolol <5 5 - - <5 3 - - 
ZM 241385 5.85 ± 0.20 5 6.1-6.6 11,12 6.63 ± 0.09 3 6.1 11 
XAC 7.09 ± 0.19 4 7.6 18 7.70 ± 0.13 3 7.0-7.4 8-10 
PSB 603 6.33 ± 0.16 4 <5 19 6.31 ± 0.14 4 <5 19 
15.  Kim, Y.C., Ji, X.D. & Jacobson, K.A. J. Med. Chem. 39, 4142–4148 (1996). 
16.  Sullivan, G.W., Rieger, J.M., Scheld, W.M., Macdonald, T.L. & Linden, J. Br. J. 
Pharmacol. 132, 1017–1026 (2001). 
17.  Yates, L. et al. Auton Autacoid Pharmacol. 26, 191–200 (2006). 
18.  Jockers, R. et al. J. Biol. Chem. 269, 32077–32084 (1994). 
19.  Borrmann, T. et al. J. Med. Chem. 52, 3994–4006 (2009). 
20.  Baker, J.G. & Hill, S.J. J. Pharmacol. Exp. Ther. 320, 218–228 (2007). 
 
 
 
 
 
 
 
 
 
 
  
Supplementary Table 2  
pKi values at Nluc-A1 and Nluc-A3 receptors using different fluorescent ligands 
! Nluc-A1 receptor Nluc-A3 receptor 
ABEA-X-BY630 ABEA-X-BY630 AV039 
pKi 
 
pKi 
 
pKi 
Co-addition Preincubation Co-addition Preincubation Co-addition 
CGS 15943 8.17 ± 0.25 8.20 ± 0.12 7.54 ± 0.19 7.87 ± 0.04 7.13 ± 0.14 
MRS 1220 6.97 ± 0.23 7.31 ± 0.12  8.91 ± 0.14 9.05 ± 0.07 8.26 ± 0.12 
SCH 58261 6.54 ± 0.21  6.12 ± 0.06  5.09 ± 0.06 
DPCPX 8.49 ± 0.13 8.56 ± 0.11 6.02 ± 0.11 6.54 ± 0.05 5.47 ± 0.17 
PSB 603 5.70 ± 0.13  5.93 ± 0.13  5.91 ± 0.09 
XAC 7.40 ± 0.12 7.50 ± 0.13 6.96 ± 0.10 7.44 ± 0.06 6.64± 0.11 
ZM 241385 6.33 ± 0.12  6.03 ± 0.08  5.49 ± 0.04 
propranolol <5  <5  <5 
We obtained pKi values (mean ± s.e.m.; n = 4) in the NanoBRET binding assay using 
whole, live HEK293 cells expressing Nluc-A1 or Nluc-A3 receptor.  We used 250 nM 
ABEA-X-BY630 in Nluc-A1 receptor-expressing cells, 50 nM ABEA-X-BY630 in Nluc-
A3 receptor-expressing cells and 10 nM AV039 in Nluc-A3 receptor-expressing cells. We 
added unlabeled ligand simultaneously with fluorescent ligand (Co-addition). Alternatively, 
in order to check for differences in pKi values determined with the fluorescent agonist 
ABEA-X-BY630 due to simultaneous addition, we also investigated the values obtained for 
four antagonists following a 30 min preincubation with the antagonist prior to addition of 
ABEA-X-BY630 (Preincubation).  
Note: Using 3H-DPCPX in live CHO cells expressing the wild-type A1 receptor, we have 
previously published pKi values for DPCPX, XAC and CGS15943 of 8.37 ± 0.03, 7.25 ± 
0.02 and 8.35 ± 0.05 respectively1. These are very similar to the respective values quoted 
for Nluc-A1 receptor with ABEA-X-BY630 above. 
1. Baker, J.G. & Hill, S.J. J. Pharmacol. Exp. Ther. 320, 218–228 (2007). 
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